The Management of Major Depressive Disorder: Synopsis of the 2022 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
DESCRIPTION: In February 2022, the U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) approved a joint clinical practice guideline (CPG) for the management of major depressive disorder (MDD). This synopsis summarizes key recommendations. METHODS: Senior leaders within the VA and the DoD assembled a team to update the 2016 CPG for the management of MDD that included clinical stakeholders and conformed to the National Academy of Medicine's tenets for trustworthy CPGs. The guideline panel developed key questions, systematically searched and evaluated the literature, created two 1-page algorithms, and distilled 36 recommendations for care using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. Select recommendations that were identified by the authors to represent key changes from the prior CPG are presented in this synopsis. RECOMMENDATIONS: The scope of the CPG is diverse; however, this synopsis focuses on key recommendations that the authors identified as important new evidence and changes to prior recommendations on pharmacologic management, pharmacogenomics, psychotherapy, complementary and alternative therapies, and the use of telemedicine.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32279-7 · Cited by 13,867
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
The Economic Burden of Adults With Major Depressive Disorder in the United States (2005 and 2010)
Greenberg, P. E., Fournier, A.-A., Sisitsky, T., Pike, C. T., & Kessler, R. C. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09298 · Cited by 1,779
Andrews, J., Guyatt, G., Oxman, A. D., Alderson, P., Dahm, P., Falck-Ytter, Y., Nasser, M., Meerpohl, J., Post, P. N., Kunz, R., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.03.013 · Cited by 1,416
Blumberger, D. M., Vila-Rodriguez, F., Thorpe, K. E., Feffer, K., Noda, Y., Giacobbe, P., Knyahnytska, Y., Kennedy, S. H., Lam, R. W., Daskalakis, Z. J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30295-2 · Cited by 1,363 · cited 1×
“A study of the clinical effectiveness, safety, and tolerability of intermittent TBS (iTBS) compared with standard 10-Hz rTMS in adults with TRD showed that 10-Hz rTMS did not provide more benefit than iTBS (30).”
MethodAndrews, J. C., Schünemann, H. J., Oxman, A. D., Pottie, K., Meerpohl, J. J., Coello, P. A., Rind, D., Montori, V. M., Brito, J. P., Norris, S., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.02.003 · Cited by 1,315
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Karyotaki, E., Efthimiou, O., Miguel, C., Maas genannt Bermpohl, F., Furukawa, T. A., Cuijpers, P., Individual Patient Data Meta-Analyses for Depression (IPDMA-DE) Collaboration, Riper, H., Patel, V., Mira, A., et al. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.4364 · Cited by 866
Daly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1189 · Cited by 795
Effects of evidence-based clinical practice guidelines on quality of care: a systematic review
Lugtenberg, M., Burgers, J. S., & Westert, G. P. (2009) · Quality and Safety in Health Care · doi:10.1136/qshc.2008.028043 · Cited by 478
Cited by
Jha, M. K., & Mathew, S. J. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230025 · Cited by 114
Schnurr, P. P., Hamblen, J. L., Wolf, J., Coller, R., Collie, C. F., Fuller, M. A., Holtzheimer, P. E., Kelly, U. A., Lang, A. J., McGraw, K., et al. (2024) · Annals of Internal Medicine · doi:10.7326/m23-2757 · Cited by 111
“Evidence was insuf-fi cient to make a recommendation for or against other technological methods, such as mobile apps (recommendations 30 and 31).”
MethodSelf-citationCrowley, M. J., Tarkington, P. E., Bosworth, H. B., Jeffreys, A. S., Coffman, C. J., Maciejewski, M. L., Steinhauser, K., Smith, V. A., Dar, M. S., Fredrickson, S. K., et al. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.2947 · Cited by 75
New and emerging treatments for major depressive disorder
Njenga, C., Ramanuj, P., de Magalhães, F. J. C., & Pincus, H. A. (2024) · BMJ · doi:10.1136/bmj-2022-073823 · Cited by 59
“79 The guidelines also recommend the use of rTMS in such patients but not TBS, concluding that the strength of the evidence is too low to justify a recommendation.”
BackgroundPharmacogenomic Clinical Support Tools for the Treatment of Depression
Baum, M. L., Widge, A. S., Carpenter, L. L., McDonald, W. M., Cohen, B. M., & Nemeroff, C. B. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230657 · Cited by 36
Eapen, B. C., Tran, J., Ballard‐Hernandez, J., Buelt, A., Hoppes, C. W., Matthews, C. T., Pundik, S., Reston, J., Tchopev, Z. N., Wayman, L. M., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-02205 · Cited by 38
Self-citationThe Quest for Secondary Pharmaceuticals: Drug Repurposing/Chiral-Switches Combination Strategy
D’Acquarica, I., & Agranat, I. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00151 · Cited by 34
Impact of Antidepressants on Weight Gain: Underlying Mechanisms and Mitigation Strategies
Mouawad, M., Nabipur, L., & Agrawal, D. K. (2025) · Archives of Clinical and Biomedical Research · doi:10.26502/acbr.50170450 · Cited by 39
“They concluded that while there is interest in pharmacogenomic approaches, the evidence is currently insufficient to make a strong recommendation for its routine use due to mixed outcomes and low-quality evidence [123].”
Increased odds of metabolic syndrome among adults with depressive symptoms or antidepressant use
Meshkat, S., Duffy, S. F., Tassone, V. K., Lin, Q., Pang, H. Y. M., Jung, H., Lou, W. Y. W., & Bhat, V. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03289-4 · Cited by 27
“The statistical analysis plan and analytic code that supports the fi ndings of this study are available from the corresponding author, VB, upon reasonable request.”
Clinical management of major depressive disorder with comorbid obesity
Opel, N., Hanßen, R., Steinmann, L. A., Roempler, J., Köhler‐Forsberg, O., Hahn, M., Ferretti, F., Palmer, C., Penninx, B. W. J. H., Gold, S. M., et al. (2025) · The Lancet Psychiatry · doi:10.1016/s2215-0366(25)00193-2 · Cited by 24
Pharmacological Monotherapy for Depressive Disorders: Current and Future—A Narrative Review
Gao, K., Oruc, E. B., & Koparal, B. (2025) · Medicina · doi:10.3390/medicina61040558 · Cited by 14
“…SNRIs, and bupropion) are the first-line antidepressants for a current depressive episode of MDD recommended by the American Psychological Association (APA) [151], Veterans Administration/Department of Defense (VA/DOD) [152], and the Canadian Network for Mood and Anxiety Treatments (CAN-MAT) [153].”
Tredici, A. L. D., Johnson, H. L., DeHart, W. B., Gutin, A., Morin, P. E., Kasten, C. R., Becker, L. K., Taber, K. J., Chawla, D., & Nierenberg, A. A. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001999 · Cited by 10
Multifamily group treatment for veterans with mood disorders: A pilot study.
Sherman, M. D., Fischer, E. P., Owen, R. R., Lu, L., & Han, X. (2015) · Couple and Family Psychology Research and Practice · doi:10.1037/cfp0000040 · Cited by 13
Reis, D. J., Kaizer, A. M., Kinney, A. R., Bahraini, N. H., Forster, J. E., & Brenner, L. A. (2022) · Psychological Trauma Theory Research Practice and Policy · doi:10.1037/tra0001304 · Cited by 14
IsHak, W. W., Hirsch, D., Renteria, S., Totlani, J., Murphy, N., Chang, T. Y., Abdelsalam, R., Salem, M., Meyer, A., Keerthana, S., et al. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-07141-3 · Cited by 13
“Esketamine was not included in the 2016 guideline as it was not commercially available at that time [114].”
InfluentialHain, D. T., Tredici, A. L. D., Griggs, R. B., Law, R. A., Mabey, B., Johnson, H. L., Taber, K. J., Lynch, K. G., Gutin, A., & Oslin, D. W. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1658616 · Cited by 10
Self-citationFernandes-Nascimento, M. H., Negrão, A. B., Viana-Ferreira, K., Chaves, B. R., & Wang, Y. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2276230 · Cited by 9
Zainal, N. H. (2023) · Psychological Medicine · doi:10.1017/s0033291723003306 · Cited by 10
Current Suicidal Ideation Among Treatment-Engaged Active-Duty Soldiers and Marines
Zimmerman, L., Villatte, J. L., Kerbrat, A. H., Atkins, D. C., Flaster, A., & Comtois, K. A. (2015) · Military Behavioral Health · doi:10.1080/21635781.2015.1093980 · Cited by 5
Dextromethorphan/bupropion in major depressive disorder: a profile of its use
Blair, H. A. (2023) · Drugs & Therapy Perspectives · doi:10.1007/s40267-023-01009-w · Cited by 5
“More recently, an updated joint clinical practice guideline from the US Department of Veterans Affairs and US Department of Defense included a number of new interventions, such as ketamine and esketamine (not recommended as initial treatment but reserved for patients for whom previous therapies have failed or were not…”
BackgroundBlanco, J., Quimbaya, P., Mena, M., Dodd, S., & Bustos, R. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2374024 · Cited by 6
“The American Psychiatric Association (APA) guidelines from 2010 and the Department of Defense veterans’ consensus from 2022 recommend initiating pharmacological treatment accompanied by psychotherapy in adults with moderate to severe depressive disorders [10,11].”
Javaheri, E. D., Wie, C. S., Covington, S. M., Misra, L., Pew, S., Viswanath, O., Freeman, J., & Maloney, J. A. (2025) · Current Pain and Headache Reports · doi:10.1007/s11916-025-01408-w · Cited by 4
Patricio, P., & Massé‐Alarie, H. (2025) · Brain Sciences · doi:10.3390/brainsci15070760 · Cited by 5
“The democratization of the use of NIBS in the clinical field is probably secondary to its recommendations as a potential treatment in clinical guidelines for the management of certain conditions such as depression [12] and neuropathic pain [13].”
Ethnopsychopharmacology: Clinical and scientific writing pearls
Leung, J. G. (2023) · Mental Health Clinician · doi:10.9740/mhc.2023.12.276 · Cited by 3
“45 – 47 As a further example, the American Academy of Child and Adolescent Psychiatry issued a 2022 policy statement recommending against the use of “ pharmacogenetic testing to select psychotropic medications in children and adolescents.”
BackgroundA framework for inferring and analyzing pharmacotherapy treatment patterns
Rush, E. N., Özmen, Ö., Kim, M., Ortegon, E. R., Jones, M., Park, B. H., Pizer, S. D., Trafton, J. A., Brenner, L. A., Ward, M. C., et al. (2024) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-024-02469-4 · Cited by 5
“For example, there is disagreement on the second and third-line medications for MDD [2, 38, 39].”
BackgroundMiller, D. C., Chawla, D., Taber, K. J., Payne, J. L., & Tredici, A. L. D. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-06977-z · Cited by 5
“Clinical guidelines for treatment of PPD recommend either or both psychotherapy and pharmacotherapy as first-line, depending on the severity of the illness and past history of response to antidepressants [5, 11, 12].”
Considering New and Emerging Treatment Strategies for Depression: Beyond STAR*D and the Monoamines
McInnes, L. A., & Marton, T. F. (2024) · Current Psychiatry Research and Reviews · doi:10.2174/0126660822284575240130053259 · Cited by 4
Levis, M., Dimambro, M., Levy, J., Platt, H., Fraade, A., & Shiner, B. R. (2025) · Clinical Psychology & Psychotherapy · doi:10.1002/cpp.70041 · Cited by 2
Sampson, E. (2023) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20230424-01 · Cited by 2
VA/Department of Defense Clinical Practice Guideline for PTSD and ASD
Schnurr, P. P., Sall, J. A., & Riggs, D. S. (2024) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.1238 · Cited by 5
Self-citationDifficult to Treat Depression: Focus on Approach, Algorithms, and Access
Karp, J. F., Brinton, R. D., Fournier, J. C. J., Harding, L., Jha, M. K., Lenze, E. J., Mathew, S. J., Meltzer-Brody, S. E., Mohr, D. C., Riva‐Posse, P., et al. (2024) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.psprmdd2408ah · Cited by 5
“46 The recommendations prioritize engaging in discussions with patients and making clinical decisions tailored to individual patient characteristics rather than adhering to a generalized recommendation.”
Self-citationThe clinical utility of newer antidepressant agents: Understanding the role in management of MDD
Waters, K. (2022) · Mental Health Clinician · doi:10.9740/mhc.2022.10.309 · Cited by 3
Pharmacological treatment for mental health illnesses in adults receiving dialysis: A scoping review
Wichart, J., Yoeun, P., Chin, T., Evernden, C., Berendonk, C., Kerr, J., Birchall, A., Boschee, B., Defoe, K., Dhaliwal, J., et al. (2024) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.13022 · Cited by 3
“Clinical guidelines suggest that methylphenidate [92] or lithium [92, 93] may be used as depression adjunctive therapies.”
Tucher, E. L., Steele, A. L., Uratsu, C. S., Hamilton, L., Brown, M. C., Nugent, J. R., Jones, D. H., Gottlieb, L. M., & GRANT, R. W. (2025) · Contemporary Clinical Trials · doi:10.1016/j.cct.2025.108210 · Cited by 3
Cohen, R., Bastos, J., Cunha, C., Marguilho, M., Sancho, A. V., Silva, M. J. M., King, F., & Castro-Rodrigues, P. (2026) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2026.02.001 · Cited by 3
Lee, C.-H. J., Qian, Y., Yu, W., Cusin, C., & Sheng‐Kai, K. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121487 · Cited by 1
Levis, M., Dimambro, M., Levy, J., Nerish, M., Riblet, N. B. V., & Shiner, B. R. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117148 · Cited by 1
Sun, S., Wei, Z., Yang, X., 姚彩娟, Liu, Z., Li, R., & 匡小娟 (2026) · European Journal of Integrative Medicine · doi:10.1016/j.eujim.2026.102686 · Cited by 1
Gabriela Ribeiro, P. E. N. A., Zonzini, F. H. T., & Bonetti, A. D. F. (2024) · Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde · doi:10.30968/rbfhss.2024.154.1122
Kennedy, K. P., Heldt, J. P., & Oslin, D. W. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002025 · Cited by 3
Self-citationCosts for Long-Term Health Care After a Police Shooting in Ontario, Canada
Raza, S., Thiruchelvam, D., & Redelmeier, D. A. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.35831
“45 Median (IQR) 198 (71-506) 213 (95-473) .”
InfluentialSwanson, L. N., Jones, L. S., Aycart, J. M., Zhu, Z., Rabin, D. M., & Kuhn, T. P. (2024) · medRxiv · doi:10.1101/2024.01.30.24301798
“While most consensus groups recommend consideration of ketamine only after other antidepressant options have been exhausted, 13,24,25 our findings provide evidence that ketamine’s antidepressant efficacy is not exclusive to advanced cases of treatment-resistance.”
BackgroundReview of Guidelines on Bupropion for Depression
CDA-AMC (2024) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2024.1014
McQuaid, J. R., & Breland‐Noble, A. M. (2025) · Cambridge University Press eBooks · doi:10.1017/9781009086264.003
Self-citationKetamine for depression and other psychiatric diseases
Roth, W. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29930-8.00005-9
Müller, S., Keller, A., Wagner, T., & Hoffmann, L. (2021) · Specialty journal of Pharmacognosy Phytochemistry and Biotechnology · doi:10.51847/zgnkximaii
Levis, M., Dimambro, M., Levy, J., & Shiner, B. R. (2026) · Administration and Policy in Mental Health and Mental Health Services Research · doi:10.1007/s10488-026-01495-w
“While the VA has worked extensively to roll-out EBPs (Rosen et al., 2016 ; Schnurr et al., 2022), and utilization rates are increasing (Maguen et al., 2018 ; McQuaid et al., 2022), MDD EBP usage rates remain very low in our sample, especially for non-high-risk cases.”
Ketamine for Depression in Serious Illness: Evidence, Safety, and Practical Approaches
Noufi, P. E., Borris, J. B., Chammas, D., McDermott, C. L., Ufere, N. N., Webb, J. A., & Shalev, D. (2026) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2026.04.604 · Cited by 1
Yakovleva, O. B., Сафарова, Т. П., & Savushkina, O. K. (2026) · Psikhiatriya · doi:10.30629/2618-6667-2026-24-2-15-27
Swartz, H. A. (2026) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.20260023
Estela-Fernandez, C. A., Elsheikh, R. M. Y., Beatrice, D. F., Alhendal, A. A., Ewe, C. I., Montesinos, S. Y., Wensel, J., Mishra, A. P., Yousif, A. A., & Ali, H. T. (2026) · Neuropsychiatrie · doi:10.1007/s40211-026-00584-4
Meyerson, W. U., Cai, T., & Smoller, J. W. (2026) · medRxiv · doi:10.64898/2026.07.17.26358340
THE IMPACT OF INTRANASAL ESKETAMINE ON TREATMENT-RESISTANT DEPRESSION: A SYSTEMATIC REVIEW
Kotlarski, W., Kotlarska, K. M., Mainka, T. S., & Sergejuk, E. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5523
Ma, C.-H., Chen, K.-Y., Chen, T.-T., Huang, W., & Gau, S. S. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122388
CACA Guidelines for holistic integrative assessment (2025)
Zhang, H., Shi, Q., Li, X., Li, Q., Liu, Y., Zhang, H., Lin, R., Zhou, W., Chu, Q., Min, J., et al. (2026) · Holistic Integrative Oncology · doi:10.1007/s44178-026-00277-6
“In clinical practice it is essential to understand the advantages and limitations of different screening and assessment tools and to select the one that best fits the specific context [13].”
Übergewicht als Komorbidität bei psychischen Erkrankungen
Opel, N., & Thanarajah, E. E. (2026) · Springer eBooks · doi:10.1007/978-3-662-72335-7_27
Meyerson, W. U., Cai, T., & Smoller, J. W. (2026) · Psychological Medicine · doi:10.1017/s0033291726106321
“…hazard ratio a 0.470 0.420 to 0.530 (Zhou et al., 2022) Model structure Continuation phase after remission, months 8 Fixed (Lam et al., 2024; McQuaid et al., 2022) Monitoring interval (active monitoring), months 3 1, 3, 6 b…”
Influential
Metadata
- Authors
- McQuaid, J. R., Buelt, A., Capaldi, V., Fuller, M., Issa, F., Lang, A. E., Hoge, C., Oslin, D. W., Sall, J., Wiechers, I. R., & Williams, S.
- Affiliations
- University of California, San Francisco (US)
- C.W. Bill Young VA Medical Center (US)
- Uniformed Services University of the Health Sciences (US)
- United States Department of Veterans Affairs (US)
- Defense Health Agency (US)
- Virginia Commonwealth University (US)
- Walter Reed Army Institute of Research (US)
- Philadelphia VA Medical Center (US)
- Veterans Administration (US)
- Case Western Reserve University (US)
- ORCID
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2022-10
- Volume
- 175
- Issue
- 10
- Pages
- 1440-1451
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W4296460212
- Semantic Scholar
- 174bc4c3e69c5fa6b69648ea0d34dd50176ed02e
- Cited by
- 59
- References
- 36
- Citations by year
- 2026: 17 · 2025: 16 · 2024: 12 · 2023: 8 · 2022: 3
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
- Keywords
- major depressive disorder, veterans, pharmacological management, pharmacogenomics, psychotherapy, complementary and alternative medicine, telemedicine, guideline recommendations
- MeSH terms
- Major Depressive Disorder, Humans, United States, United States Department of Veterans Affairs, Veterans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.